Recent share performance and business overview

Veracyte (VCYT) stock has caught investor attention after a strong month and past 3 months, with the share price up about 40% over the month and 32% over the past 3 months.

The diagnostics company focuses on genomic tests such as Afirma for thyroid nodules, Decipher classifiers for prostate and bladder cancer, Prosigna for breast cancer, and Percepta for lung cancer, alongside nCounter analysis system services.

That strong 30 day share price return of 40% sits alongside a 1 year total shareholder return of 73.3% and a 3 year total shareholder return of 78.8%. This points to momentum that has been building rather than fading.

If Veracyte’s move has you looking across the sector, this is a good moment to scan for other genomic and healthcare AI opportunities using our screener of 39 healthcare AI stocks

With the stock up strongly and trading only slightly below a published analyst price target, plus an indicated intrinsic discount of about 14%, you should ask whether Veracyte still offers a buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 1% Undervalued

Veracyte’s most followed narrative points to a fair value of about $47.00, only slightly above the last close at $46.34. This puts the focus squarely on the quality and durability of the growth story rather than a big valuation gap.

Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

Curious what kind of revenue trajectory, margin profile, and future earnings multiple have to line up to support that fair value number? The narrative leans on a tightly defined growth path, specific profitability assumptions, and a premium valuation hurdle that together paint a very particular picture of where Veracyte could be headed.

Result: Fair Value of $47.00 (UNDERVALUED)

However, there are still clear watchpoints, including Veracyte’s reliance on core tests like Decipher and Afirma, as well as ongoing reimbursement and regulatory pressures that could unsettle this narrative.

Another angle on valuation

The narrative leans on a discounted cash flow output of about $54.06 per share, which points to Veracyte trading at roughly a 14% discount to that fair value. By contrast, the current P/E around 42x is roughly double both peers at 21.2x and a fair ratio of 17.3x. How comfortable are you paying that kind of earnings premium?

Next Steps

If this mix of optimism and tension around valuation has your attention, do not sit on the sidelines. Pressure test the thesis yourself by reviewing the 3 key rewards

Looking for more investment ideas?

If Veracyte has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly surface other targeted ideas that could round out your watchlist.

• Target potential value opportunities by scanning 46 high quality undervalued stocks. These combine quality fundamentals with prices that may not fully reflect them.
• Build resilience into your portfolio by checking 64 resilient stocks with low risk scores. These score well on financial stability and lower risk profiles.
• Spot less crowded opportunities by searching the screener containing 22 high quality undiscovered gems. These pair solid business quality with relatively low investor attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.